- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Interventions
- 30 µg/strain of Quadrivalent VLP Vaccine, 60 µg/strain of Quadrivalent VLP Vaccine, FluLaval® Tetra (15 µg/strain), Fluzone® High-Dose (60 µg/strain)
- Biological
- Lead sponsor
- Medicago
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,001 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Redding, California • Hollywood, Florida • South Miami, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 829 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
- Conditions
- Influenza
- Interventions
- Influsplit Tetra™ vaccine produced by investigational process (IP), Influsplit Tetra™ vaccine produced by licensed process (LP)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Months to 49 Years
- Enrollment
- 1,886 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 4
- States / cities
- Wichita, Kansas • Rochester, New York • Warwick, Rhode Island + 1 more
- Conditions
- Influenza, Human
- Interventions
- aQIV or aTIV, QIV or TIV
- Biological
- Lead sponsor
- Seqirus
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 38,769 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 111
- States / cities
- Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 96 more
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Interventions
- 15 µg/strain of Quadrivalent VLP Vaccine, 30 µg/strain of Quadrivalent VLP Vaccine, 15 µg/strain of the licensed quadrivalent vaccine
- Biological
- Lead sponsor
- Medicago
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 900 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016
- U.S. locations
- 3
- States / cities
- Hollywood, Florida • South Miami, Florida • Endwell, New York
- Conditions
- Influenza Immunization
- Interventions
- Recombinant influenza vaccine (RIV4), Quadrivalent influenza vaccine (IIV4)
- Biological
- Lead sponsor
- Sanofi Pasteur, a Sanofi Company
- Industry
- Eligibility
- 3 Years to 8 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Jonesboro, Arkansas • San Diego, California + 14 more
- Conditions
- Seasonal Influenza
- Interventions
- mRNA-1010, Fluarix®, Influsplit® Tetra, Fluarix Tetra, Alpharix® Tetra
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 40,805 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 188
- States / cities
- Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 150 more